Clear Search

Showing 1 result for “Readie A”.

June 2023

Two‑Year Imaging Outcomes from a Phase 3 Randomized Trial of Secukinumab in Patients with Non‑Radiographic Axial Spondyloarthritis

Arthritis Res Ther. 2023;16;25(1):80 doi 10.1186/s13075-023-03051-5

Braun et al. studied a large cohort of patients with nr-axSpA, that demonstrated a secukinumab reduced SI joint inflammation (BME), this reduction was sustained over 104 weeks, from an overall low baseline level of spinal inflammation or structural damage.

suite…